Germany clears pelareorep pancreatic cancer trial continuation
Authorities in Germany have given Oncolytics Biotech the go-ahead to continue enrollment in a Phase 1/2 clinical trial testing the company’s viral therapy pelareorep…
News
FDA grants orphan drug status to novel brain cancer treatment
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to a novel brain cancer treatment — one designed for malignant gliomas…
Medicaid expansion can raise demand for gynecologic cancer care
An expansion of Medicaid services in the state of Virginia led within months to more young and middle-aged women of lower income being treated in…
Under-the-skin Sarclisa found as effective as approved formulation
A subcutaneous, or under-the-skin, formulation of Sarclisa (isatuximab) is just as effective as the approved intravenous (into-the-vein) version of the therapy at controlling treatment-resistant…
FDA gives LYT-200 fast track status as potential AML treatment
The U.S. Food and Drug Administration (FDA) has granted fast track designation to Puretech Health’s LYT-200, an investigative treatment for acute myeloid leukemia…
MEK inhibitor IMM-1-104 shows promise in pancreatic cancer: Data
Investigational oral therapy IMM-1-104 was well tolerated and showed early signs of efficacy as a first- or second-line treatment for pancreatic cancer. That’s according…
Brainchild Bio planning pivotal trial of CAR T-cell therapy for DIPG
Brainchild Bio plans to launch a pivotal Phase 2 clinical trial to test its investigational cell therapy BCB-276 in patients with diffuse intrinsic pontine…
FDA reviewing oral combination treatment for ovarian cancer
The U.S. Food and Drug Administration (FDA) has agreed to review Verastem Oncology’s application seeking approval of a combination of avutometinib and defactinib for…
Minimal residual disease is potential early outcome measure in myeloma
Minimal residual disease or MRD — defined as a very small number of cancer cells that remain in the body during or after treatment —…
Antipsychotic clozapine raises blood cancer rates; overall risk is small
Treatment with the antipsychotic medication clozapine may increase the risk of blood cancers, but their overall likelihood is still low in people taking the drug,…
